Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease

Christopher L. Newman, Amy Creecy, Mathilde Granke, Jeffry S. Nyman, Nannan Tian, Max A. Hammond, Joseph M. Wallace, Drew M. Brown, Xuening (Neal) Chen, Sharon Moe, Matthew Allen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a mild antiresorptive agent that reduces fracture risk in the general population. Here we assessed the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole-bone mechanics, and material properties). Their normal littermates served as controls. Animals with CKD had significantly higher parathyroid hormone levels compared with normal controls, as well as inferior structural and mechanical skeletal properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous bone volume in the rats with CKD. Although it had little effect on cortical bone geometry, it resulted in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, achieving levels equivalent to normal controls. Animals treated with raloxifene had superior tissue-level mechanical properties as assessed by nanoindentation, and higher collagen D-periodic spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole-bone mechanical properties in CKD through its impact on skeletal material properties.Kidney International advance online publication, 21 October 2015; doi:10.1038/ki.2015.315.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Oct 21 2015

Fingerprint

Cystic Kidney Diseases
Chronic Renal Insufficiency
Animal Models
Bone Density Conservation Agents
Bone and Bones
X-Ray Microtomography
Bone Remodeling
Atomic Force Microscopy
Mechanics
Parathyroid Hormone
Minerals
Publications
Raloxifene Hydrochloride
Histology
Collagen
Kidney
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. / Newman, Christopher L.; Creecy, Amy; Granke, Mathilde; Nyman, Jeffry S.; Tian, Nannan; Hammond, Max A.; Wallace, Joseph M.; Brown, Drew M.; Chen, Xuening (Neal); Moe, Sharon; Allen, Matthew.

In: Kidney International, 21.10.2015.

Research output: Contribution to journalArticle

Newman, Christopher L. ; Creecy, Amy ; Granke, Mathilde ; Nyman, Jeffry S. ; Tian, Nannan ; Hammond, Max A. ; Wallace, Joseph M. ; Brown, Drew M. ; Chen, Xuening (Neal) ; Moe, Sharon ; Allen, Matthew. / Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. In: Kidney International. 2015.
@article{2e8417ba0e7b40f0b0c52a910a499971,
title = "Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease",
abstract = "Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a mild antiresorptive agent that reduces fracture risk in the general population. Here we assessed the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole-bone mechanics, and material properties). Their normal littermates served as controls. Animals with CKD had significantly higher parathyroid hormone levels compared with normal controls, as well as inferior structural and mechanical skeletal properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous bone volume in the rats with CKD. Although it had little effect on cortical bone geometry, it resulted in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, achieving levels equivalent to normal controls. Animals treated with raloxifene had superior tissue-level mechanical properties as assessed by nanoindentation, and higher collagen D-periodic spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole-bone mechanical properties in CKD through its impact on skeletal material properties.Kidney International advance online publication, 21 October 2015; doi:10.1038/ki.2015.315.",
author = "Newman, {Christopher L.} and Amy Creecy and Mathilde Granke and Nyman, {Jeffry S.} and Nannan Tian and Hammond, {Max A.} and Wallace, {Joseph M.} and Brown, {Drew M.} and Chen, {Xuening (Neal)} and Sharon Moe and Matthew Allen",
year = "2015",
month = "10",
day = "21",
doi = "10.1038/ki.2015.315",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease

AU - Newman, Christopher L.

AU - Creecy, Amy

AU - Granke, Mathilde

AU - Nyman, Jeffry S.

AU - Tian, Nannan

AU - Hammond, Max A.

AU - Wallace, Joseph M.

AU - Brown, Drew M.

AU - Chen, Xuening (Neal)

AU - Moe, Sharon

AU - Allen, Matthew

PY - 2015/10/21

Y1 - 2015/10/21

N2 - Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a mild antiresorptive agent that reduces fracture risk in the general population. Here we assessed the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole-bone mechanics, and material properties). Their normal littermates served as controls. Animals with CKD had significantly higher parathyroid hormone levels compared with normal controls, as well as inferior structural and mechanical skeletal properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous bone volume in the rats with CKD. Although it had little effect on cortical bone geometry, it resulted in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, achieving levels equivalent to normal controls. Animals treated with raloxifene had superior tissue-level mechanical properties as assessed by nanoindentation, and higher collagen D-periodic spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole-bone mechanical properties in CKD through its impact on skeletal material properties.Kidney International advance online publication, 21 October 2015; doi:10.1038/ki.2015.315.

AB - Patients with chronic kidney disease (CKD) have an increased risk of fracture. Raloxifene is a mild antiresorptive agent that reduces fracture risk in the general population. Here we assessed the impact of raloxifene on the skeletal properties of animals with progressive CKD. Male Cy/+ rats that develop autosomal dominant cystic kidney disease were treated with either vehicle or raloxifene for five weeks. They were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole-bone mechanics, and material properties). Their normal littermates served as controls. Animals with CKD had significantly higher parathyroid hormone levels compared with normal controls, as well as inferior structural and mechanical skeletal properties. Raloxifene treatment resulted in lower bone remodeling rates and higher cancellous bone volume in the rats with CKD. Although it had little effect on cortical bone geometry, it resulted in higher energy to fracture and modulus of toughness values than vehicle-treated rats with CKD, achieving levels equivalent to normal controls. Animals treated with raloxifene had superior tissue-level mechanical properties as assessed by nanoindentation, and higher collagen D-periodic spacing as assessed by atomic force microscopy. Thus, raloxifene can positively impact whole-bone mechanical properties in CKD through its impact on skeletal material properties.Kidney International advance online publication, 21 October 2015; doi:10.1038/ki.2015.315.

UR - http://www.scopus.com/inward/record.url?scp=84944929644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944929644&partnerID=8YFLogxK

U2 - 10.1038/ki.2015.315

DO - 10.1038/ki.2015.315

M3 - Article

C2 - 26489025

AN - SCOPUS:84944929644

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -